BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37972062)

  • 1. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
    Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
    Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
    Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
    Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferroptosis-Related Gene
    Peng B; Peng J; Kang F; Zhang W; Peng E; He Q
    Front Cell Dev Biol; 2022; 10():881447. PubMed ID: 35517502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
    Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
    Front Immunol; 2022; 13():982628. PubMed ID: 36325340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
    Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
    Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of Metallothionein 1 G (MT1G) Negatively Regulates Ferroptosis in Clear Cell Renal Cell Carcinoma by Reducing Glutathione Consumption.
    Zhang W; Luo M; Xiong B; Liu X
    J Oncol; 2022; 2022():4000617. PubMed ID: 36204178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
    Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
    J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma.
    Liu L; Jin H; Dong M; Tian J; Li H; Liu Q; Chen Y; Zou Z
    Apoptosis; 2022 Dec; 27(11-12):946-960. PubMed ID: 36028785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
    Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
    Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.
    JiaWei Z; ChunXia D; CunDong L; Yang L; JianKun Y; HaiFeng D; Cheng Y; ZhiPeng H; HongYi W; DeYing L; ZhiJian L; Xiao X; QiZhao Z; KangYi X; WenBing G; Ming X; JunHao Z; JiMing B; ShanChao Z; MingKun C
    Ann Med; 2021 Dec; 53(1):730-740. PubMed ID: 34032524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy.
    Shi Y; Wang Y; Dong H; Niu K; Zhang W; Feng K; Yang R; Zhang Y
    Apoptosis; 2023 Oct; 28(9-10):1423-1435. PubMed ID: 37369808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer.
    Wu W; Wang X; Le W; Lu C; Li H; Zhu Y; Chen X; An W; Xu C; Wu Q; Wang L
    Front Immunol; 2022; 13():1001297. PubMed ID: 36700224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer.
    Liu SJ; Yang YB; Zhou JX; Lin YJ; Pan YL; Pan JH
    Dis Markers; 2021; 2021():2385406. PubMed ID: 34868391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-Scale Transcriptome Data Analysis Identifies KIF2C as a Potential Therapeutic Target Associated With Immune Infiltration in Prostate Cancer.
    Zhang P; Gao H; Ye C; Yan R; Yu L; Xia C; Yang D
    Front Immunol; 2022; 13():905259. PubMed ID: 35720323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration.
    Cui X; Yu H; Yao J; Li J; Li Z; Jiang Z
    BMC Cancer; 2022 Dec; 22(1):1350. PubMed ID: 36564767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment.
    Zhu J; Xu X; Jiang M; Yang F; Mei Y; Zhang X
    Front Oncol; 2023; 13():1145380. PubMed ID: 37051544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
    Liu Z; Zhong J; Zeng J; Duan X; Lu J; Sun X; Liu Q; Liang Y; Lin Z; Zhong W; Wu W; Cai C; Zeng G
    Front Immunol; 2021; 12():735170. PubMed ID: 34531875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Validation of a Prognostic Signature for Prostate Cancer Based on Ferroptosis-Related Genes.
    Liu H; Gao L; Xie T; Li J; Zhai TS; Xu Y
    Front Oncol; 2021; 11():623313. PubMed ID: 34336641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms.
    Chang P; Chen S; Chang X; Zhu J; Tang Q; Ma L
    Eur J Med Res; 2022 Jul; 27(1):115. PubMed ID: 35818069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
    Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.